RepliCel Life Sciences Inc (CE) (REPCF) Noticias

Check out MYMX, an M&A potential target in my opinion.

Yup! Mymetics Corp. (MYMX), a swiss based public company is another sleeper. Check it out!

There are 2...AMF$ and MGCL#. One Canadian, the other Australian. REPCF is positioned very well. YOFOTO is a great partner to have, plus the studies to date are very encouraging. VERY LONG!!!

REPCF

Which is the other company. Thanks! I'm letting peopke know about this

There are many sleepers among the 10k+ OTC stocks. In addition, it's a foreign company. I have another sleeper that's Australian and having the same issue. The company has hit a major milestone and hopefully as this deal progresses, the positive effect will become obvious to the masses. For now, try to get the word out.

REPCF

How is nobody aware of this stock ?

Well, looks like the deal with YOFOTO is official!! Big step here for Replicel. LONG this ticker.

This is a big development!! This company is very unknown right now. With this deal, we will get on many more radars. The OS is at 21 million according to TD Ameritrade. That is extremely low!! This ticker could easily get back to the ATH and beyond. Studies are looking very promising. Don't let this one fly by!

REPCF

Here's some links to get your DD started in the right direction:

https://replicel.com/wp-content/uploads/2017/05/RP_Presentation-2017-05.pdf - 2017 company presentation, outlines every product they have in the pipline

https://seekingalpha.com/news/3392377-replicel-life-sciences-yofoto-health-obtain-approvals-needed-complete-investment - News released today about their deal with YOFOTO

https://twitter.com/RepliCel/status/1044072708898578432 - Tweet they released last night

https://quotes.wsj.com/REPCF/financials - Some financial info at the bottom of the page

Hope this helps

Just starting to look at this, interesting the the Phase two completion and the possible launch in Japan, interested in learning more about the China deal as well, will spend some time looking into it tomorrow and in the coming week.

Is there any post here or any info anywhere that can summarize things a bit so that it will ease my initial look into the company and its pipeline. I will look further but a quick lay down would be easier after checking filings financials etc.

A few questions debt?
Dilution?
Anything more than just hair treatment, further uses being investigated etc etc.

Possible market $$?

Sorry to be so uninformed have just become aware of the company and have not had a chance to delve to deeply into just a quick perusal of the website etc.

Thanks a bunch, take care. Peace out.

Made a small error in my last post that i wanted to correct: Once (if) Shiseido takes it to market Replicel gets $31M in milestones & royalties, with payments being triggered by market launch.

Source: https://replicel.com/wp-content/uploads/2017/05/RP_Presentation-2017-05.pdf

wow I did not realize that about phase III. Pretty encouraging, I imagine if this all came to pass SP would skyrocket. Thanks!

Correct, RCH-01 is in phase II trials, testing efficiency. This is being completed by Shiseido.

Lee Buckler said on twitter that Shiseido hasn't provided a deadline for trial results but they're expecting to hear results in September/October timeframe. If the results are positive and demonstrate the treatment is effective, Japan has a law that allows for Phase III trials to be skipped and Shiseido will take it straight to market launch. If this occurs and goes to market launch before the end of the year, Shiseido pays Replicel 30 Million dollars immediately as well as milestone and royalty payments as time goes on.

Huge potential if RCH-01 goes to market, not just for the stock but also for folks suffering from hair loss.

Yeah, that was my understanding with the trials too. The deal should close with YOFOTO in the next few weeks, just in time for folks returning from the summer slumber. Should be a solid catalyst to move up back to some previous levels. Yeah, I was here too last year, but sold to get into some other plays. Now that those plays are set, I came back on a whim and stumbled across the YOFOTO deal 2 days ago. I'm a LT guy normally, so I figured I place my bet and ride it out. I'm figuring this is a stock that will take time to produce serious returns, so I have a 2--3 year horizon to allow the clinical studies to lead the way for better or worse. Although I do see this returning >1.00 within the next 6-12 months.

Replicel

thanks....I was in about a year ago but got bored with it...but after reading the last shareholder letter and given the deal with yofoto I'm convinced now is time to get back in. Have to admit I'm a little confused about the trials...rct and rcs-01 are being conducted in china and rch-01 is being handled by shiseido in japan correct?

Like many biotech's small and large, it's take time to develop these products and then have to go through the clinical studies, but the fact that Replicel is already being tagged by a well known, well capitalized company, albeit from China, is pretty huge and shouldn't be ignored. Btw, welcome aboard.

Replicel

agreed, totally under the radar

Repcf's OS is very low compared to the vast number of other OTC stocks and the company is dead set on enhancing SH value without toxic debt. How many OTC stocks can say that??

Repcf

Phase 1 clinical studies on all three products have met their endpoints and are now heading off to the next phase. All three products are potential blockbusters in the making!!

Repcf

Repcf is completely overlooked by the market, but once the deal finalizes with YOFOTO, the market will start to take notice!

REPCF

Took a small position here. Was in this last year but sold to pick up another ticker while this ticker stewed a bit. 2018 has seen very significant developments with the agreement with YOFOTO being the most obvious significant one. Look up YOFOTO. They are a powerhouse in China and should prove to be a great partner to Replicel. Also the deal is protective of shareholders with only mild dilution which is not the toxic type and for what we will get from the deal, well worth the additional shares. Now is the time to start accumulating this stock as the future is much more clear...and very bright!!!

REPCF

" In the coming weeks, shareholders should expect to see an announcement that the transaction with YOFOTO has closed, the financing complete, and a Mid-Year Update providing insights into our near-term catalysts and priorities"

Biotech with a list of upcoming catalysts and a float of 20 mill.....

Good news out if you haven't seen it.

https://www.prnewswire.com/news-releases/replicel-life-sciences-announces-signed-licensing-and-co-development-deal-for-greater-china-300679117.html

Its crazy how little attention this receives. At some point news has to come out about this baldness cure, If the old post about this being a paid pump are true that was a complete waste of revenue. HAHA!

That's absurd!

The REPCF massive paid stock promotion campaign. A sample:




Stocks Promoted : 51 Total Displaying top Viewing 1-10 | Next 10
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 0.740 Volume: 382,627
$ Intraday High: 0.770 % Change: 22.380
$ Change: 0.135 $ Volume: 283,297
$ Open: 0.623
$ Previous Close: 0.605
3 Month: $ High / Low 1.310 / 0.542 Volume 3m avg: 56,315
Promoter: Investor Ideas
Compensation: Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Date: 4/25/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 0.769 Volume: 285,852
$ Intraday High: 0.820 % Change: 0.405
$ Change: 0.003 $ Volume: 219,820
$ Open: 0.787
$ Previous Close: 0.766
3 Month: $ High / Low 1.460 / 0.542 Volume 3m avg: 35,500
Promoter: Small Cap Leader
Compensation: Smallcapleader.com has been compensated seventeen thousand dollars by a third party(Think Ink Marketing) for this investor awareness campaign regarding RepliCel Life Sciences Inc..
Date: 4/5/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 0.766 Volume: 315,643
$ Intraday High: 0.770 % Change: 13.299
$ Change: 0.090 $ Volume: 241,751
$ Open: 0.701
$ Previous Close: 0.676
3 Month: $ High / Low 1.460 / 0.542 Volume 3m avg: 31,091
Promoter: Small Cap Leader
Compensation: Smallcapleader.com has been compensated seventeen thousand dollars by a third party(Think Ink Marketing) for this investor awareness campaign regarding RepliCel Life Sciences Inc..
Date: 4/4/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 0.766 Volume: 315,643
$ Intraday High: 0.770 % Change: 13.299
$ Change: 0.090 $ Volume: 241,751
$ Open: 0.701
$ Previous Close: 0.676
3 Month: $ High / Low 1.460 / 0.542 Volume 3m avg: 31,091
Promoter: Investor Ideas
Compensation: Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Date: 4/4/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 0.717 Volume: 57,826
$ Intraday High: 0.736 % Change: -2.978
$ Change: -0.022 $ Volume: 41,450
$ Open: 0.707
$ Previous Close: 0.739
3 Month: $ High / Low 1.460 / N/A Volume 3m avg: 23,058
Promoter: Small Cap Network
Compensation: Last Updated: March 1, 2017 SmallCap Network Position AND Compensation Disclosure March 1, 2017 - SmallCap Network has been compensated $10,000 AND 200,000 restricted shares by Spyr, Inc. February 15, 2017 - SmallCap Network has been compensated $7,000 by Investor Direct Response Marketing for market awareness AND other advertising services on REPCF AND RP.V. January 17, 2017 - SmallCap Network has been compensated $10,000 AND 50,000 shares of restricted stock by Algae Dynamics Corp. March 28, 2016 - SmallCap Network has been compensated 17,500 shares of restricted stock by Staffing 360 Solutions, Inc.
Date: 3/14/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 0.680 Volume: 6,500
$ Intraday High: 0.705 % Change: -2.243
$ Change: -0.016 $ Volume: 4,420
$ Open: 0.705
$ Previous Close: 0.696
3 Month: $ High / Low 1.460 / N/A Volume 3m avg: 19,678
Promoter: Small Cap Network
Compensation: Last Updated: March 1, 2017 SmallCap Network Position AND Compensation Disclosure March 1, 2017 - SmallCap Network has been compensated $10,000 AND 200,000 restricted shares by Spyr, Inc. February 15, 2017 - SmallCap Network has been compensated $7,000 by Investor Direct Response Marketing for market awareness AND other advertising services on REPCF AND RP.V. January 17, 2017 - SmallCap Network has been compensated $10,000 AND 50,000 shares of restricted stock by Algae Dynamics Corp. March 28, 2016 - SmallCap Network has been compensated 17,500 shares of restricted stock by Staffing 360 Solutions, Inc.
Date: 3/7/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 1.214 Volume: 16,771
$ Intraday High: 1.280 % Change: -6.615
$ Change: -0.086 $ Volume: 20,360
$ Open: 1.277
$ Previous Close: 1.300
3 Month: $ High / Low 1.460 / N/A Volume 3m avg: 9,633
Promoter: Small Cap Network
Compensation: Last Updated: February 15, 2017 SmallCap Network Position AND Compensation Disclosure February 15, 2017 - SmallCap Network has been compensated $7,000 by Investor Direct Response Marketing for market awareness AND other advertising services on REPCF AND RP.V. January 17, 2017 - SmallCap Network has been compensated $10,000 AND 50,000 shares of restricted stock by Algae Dynamics Corp. March 28, 2016 - SmallCap Network has been compensated 17,500 shares of restricted stock by Staffing 360 Solutions, Inc.
Date: 2/15/2017 View:View MessageShare:Post to Facebook
Share to Twitter
Company: RepliCel Life Sciences ( REPCF )
End of Day: $ Close: 1.340 Volume: 1,700
$ Intraday High: 1.340 % Change: -0.431
$ Change: -0.006 $ Volume: 2,278
$ Open: 1.340
$ Previous Close: 1.346
3 Month: $ High / Low 1.450 / N/A Volume 3m avg: 6,620
Promoter: Alpha Stox
Compensation: is a shareholder and has been paid a consulting fee follow on Twitter | friend on Facebook | forward to a friend Copyright © 2017 Alphastox, All rights reserved.
Date: 1/12/2017 View:View MessageShare:Post to Facebook
Share to Twitter

Great new interview with Lee Buckler, the CEO:

https://www.twst.com/interview/Interview-with-the-President-CEO-and-Director-RepliCel-Life-Sciences-Inc-OTCMKTS-REPCF

TWST: How would you describe the core technology for your company, particularly when it comes to what you feel represents the most important intellectual property that you have?

Mr. Buckler: We are a biotech company with a companion medical device that has near-term applications well beyond our biologics. At the core of it, we are in the regenerative medicine space where we are taking a patient’s cells and then manufacturing a product that we then inject back into the patient for orthopedic sports injury and aesthetic applications. We are developing two different biologics comprised of different cell populations and a proprietary injector. We believe that device has significant potential to improve the way anything is injected through the skin, over the longer term for our biologics but in the near term for the dermal fillers that represent a $2 billion-plus existing market...

Alert out on RepliCel Life #Sciences, Inc. – On Verge of #Biotech #Breakthrough (OTCQB: $REPCF) (TSX.V: RP)

http://globalsmallcaps.com/2017/05/25/replicel-life-sciences-inc-on-verge-of-biotech-breakthrough/

That is a PAID STOCK PROMOTION mass distributed by a sleazy paid stock promoter:

http://globalsmallcaps.com/2017/05/25/replicel-life-sciences-inc-on-verge-of-biotech-breakthrough/

"We have received compensation of $2,500 to cover our distribution and production of this report. If additional compensation is received, future versions of the report will be updated to reflect this compensation. "


RepliCel Life #Sciences, Inc. – On Verge of #Biotech #Breakthrough (OTCQB: $REPCF) (TSX.V: RP)

http://globalsmallcaps.com/2017/05/25/replicel-life-sciences-inc-on-verge-of-biotech-breakthrough/

RepliCel Life #Sciences, Inc. – On Verge of #Biotech #Breakthrough (OTCQB: $REPCF) (TSX.V: RP)

http://globalsmallcaps.com/2017/05/25/replicel-life-sciences-inc-on-verge-of-biotech-breakthrough/

UP 21%

That is great news. Why ain't it popping??

Great news, so UnderValued

https://www.otcmarkets.com/stock/REPCF/news/United-States-Patent-Issued-to-RepliCel-for-its-Novel-Dermal-Injection-Technologies?id=156888

Management needs to update investors, or put out some news please!

I've picked up table scraps, hope we hear from company soon.

PALM BEACH, Florida, March 28, 2017 /PRNewswire/ --
The Global Regenerative Medicine Market is expected to observe the highest growth coming from the Tissue Engineering segment. By technology type, biomaterial segment currently holds the largest market share of global regenerative medicine market. However, Tissue Engineering segment is anticipated to be the fastest growing segment over the forecast period. In terms of value, the tissue engineering segment market is expected to expand at an outstanding CAGR of 17.5% over the forecast period of 2015-2019, to reach a market value of about US$ 1,070 Mn by 2019. Biotech companies in the news this week with developments of note or market performances include: RepliCel Life Sciences Inc. (OTC: REPCF)(TSXV: RP.V), Impax Laboratories, Inc. (NASDAQ: IPXL), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), Aevi Genomic Medicine, Inc. (NASDAQ: GNMX), U.S. Stem Cell, Inc. (OTC: USRM)

RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX-V: RP) is pleased to report compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel's type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. The clinical trial met its goal of establishing a complete safety profile at 6 months and showed no serious adverse events related to the study treatment or injection procedure.

Additionally, each of the treated participants, all of whom suffered chronic tendon pain and loss of function over an extended period of time with no recovery from standard treatments, showed numerous clinically important improvements by various measures including tendon composition, blood supply, physical function and pain sensation. Read this in its entirety and more news for RepliCel Life Sciences at: http://marketnewsupdates.com/news/repcf.html

"Chronic tendinosis is a state of tendon degeneration that is very difficult to reverse as is borne out by the many therapies and modalities that are used to try and treat it," stated Dr. Ross Davidson, an orthopedic surgeon, former clinical professor at the Department of Orthopaedics at the University of British Columbia, and past head physician and orthopaedic consultant for the Vancouver Canucks (of the National Hockey League (NHL)). "This study shows exciting clinical improvements in patients with clinically diagnosed chronic Achilles tendinosis who were unresponsive to standard treatments, and who had suffered for many months (in some cases, years) with frequent pain and loss of function. Not only did the study show several clinically important improvements in pain and function scores, but several ultrasound measures clearly demonstrate a marked improvement in tendon structure; something rarely seen in patients with this condition," said Davidson.

In other biomedicine/biotech news and developments:

Impax Laboratories, Inc. (NASDAQ: IPXL) closed up over 37% on Monday at $12.70 trading over 12.2 Million shares by the market close. Impax Laboratories, Inc. yesterday announced that its Board of Directors has appointed Paul M. Bisaro as Impax's President and Chief Executive Officer and a member of the Company's Board, effective March 27, 2017. Mr. Bisaro will succeed J. Kevin Buchi, who has served as Interim President and Chief Executive Officer since December of 2016. With 25 years of generic and branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished global business leader who brings a successful record of leading operational execution and corporate transformation, resulting in company growth.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) closed up on MOnday at $2.55 trading over 5 Million shares by the market close. Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States.

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) closed up over 15% on MOnday at $1.85 trading over 2.2 Million shares by the market close. Aevi Genomic Medicine, Inc. last week announced top-line results from the SAGA trial of AEVI-001 (oral non-stimulant) in adolescents with mGluR mutation positive (mGluR+) ADHD. AEVI-001 represents a novel paradigm of genomic diagnosis and treatment in neuropsychiatric disorders. The mGluR predictive biomarker enabled study of AEVI-001 in an adolescent ADHD sub-population with genetic mutations that disrupt the mGluR network and result in glutamate imbalance.

U.S. Stem Cell, Inc. (OTCQB: USRM) closed up over 25% on MOnday trading over 35.5 Million shares by the market close. U.S. Stem Cell announced earlier this month the following results from operations for the year ending December 31, 2016. "U.S. Stem Cell, Inc. continues to increase revenue, decrease liabilities, and decrease operating expenses," said Mike Tomás, President and CEO of U.S. Stem Cell, Inc. "As a world leader in stem cell research and development for degenerative conditions, we are excited about the industry's future and dedicated to making a positive impact in our patients' lives." Working with physician partners to offer over 30 protocols to patients, U.S. Stem Cell, Inc. is increasing business opportunities by expanding its services, treatments, and therapies both inside and outside the United States. Read the news in its entirety at finance.yahoo.com/news/u-stem-cell-releases-positive-210000866.html

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated six thousand nine hundred dollars for news coverage of the current press release issued by RepliCel Life Sciences Inc. by the company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:

Bottom fishing some biotechs this morning ,this one caught my eye ,Any one got any thoughts on this one ?

REPCF one for 10 reverse split:

http://otce.finra.org/DLSymbolNameChanges

.20 offering mean there is .10 discount here to share price? if the true focus is to sell to a bigger company with resources, this may be the most positive thing to happen in years.

Get ready here it comes, wait for it, wait for it...

Own this POS, The company is toast. Just another waste of time. GLTA

ONE HECK OF A BOGUS COMPANY

IT WON'T TAKE MUCH TIME TO SEE THIS COMPANY REACHING 0.000X (X = 1 TO 3)

developing potential to treat pattern baldness, let me know when they got it

why when you know it's a pump

Its been years since I even looked at this one. Now I'm gonna have to check it out.

thanks for the warning, staying clear

Great article in The Province news paper.Looks likes good thing to come for Repricel.


http://www.theprovince.com/health/seniors/Four+biotech+companies+that+helping+lead+battle+against/10890494/story.html

FOX Business Network Finally Fires
Pump & Dump Contributing Stock Pimp Tobin Smith

June 19, 2013: After "first hearing" about his penchant for pushing garbage upon an unsuspecting public, Fox Business Network, an entity of News Corp., yesterday finally fired penny stock pimp, Tobin Smith, a network contributor and regular guest on Fox's Bulls & Bears program. FBN cited his current promotion of Petrosonic Energy, Inc (PSON) a piece of cow dung, with zero cash and a book value of 3 cents, but currently trading in the high .70s, thanks in part to Mr. Smith's $50,000 paid endorsement.


Penny Stock Pimp
Tobin Smith
Smith's contract was purportedly terminated under the network's contributor policy, which states that "no contributor to FBN, nor his/her firm, and/or family members are allowed to accept financial consideration of any kind whatsoever to issue research, advertisements, or to otherwise promote individual stocks or securities." On Tuesday, The Wall Street Journal's MarketWatch reported that Smith, in a 20-page news mailer, pimped PSON.

FBN and MarketWatch's sudden revelation comes in spite of the fact that Smith has pushing the stocks of intrinsically worthless companies for years, through his company, NBT Equities Research, which offers investor relations services for small companies, for payment. Each of Smith/NBT's clients have been the subject of massive Pump & Dump campaigns, shamelessly using Smith's FBN gig as an offer of credibility. Just a few of the many stocks Smith has pimped over the years, resulting in millions of dollars in investor losses, are: Western Graphite, Inc. (WSGP), IceWeb Storage Corporation (IWEB), Velatel Global Communications (VELA), and Replicel Life Sciences (REPCF),

This website calls out Fox Business Network on it's claim that it has only now first heard about Smith's stock pimping business, as we have sent numerous proofs of Smith's breach of his contract to FBN producers.